menu
    • menu
    [{"orgOrder":0,"company":"Spexis","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"POL7306","moa":"LPS transport pathway","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Spexis \/ CARB-X","highestDevelopmentStatusID":"2","companyTruncated":"Spexis \/ CARB-X"},{"orgOrder":0,"company":"Spexis","sponsor":"University of Michigan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Balixafortide","moa":"CXCR4 ant","graph1":"Oncology","graph2":"Preclinical","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spexis \/ University of Michigan","highestDevelopmentStatusID":"4","companyTruncated":"Spexis \/ University of Michigan"},{"orgOrder":0,"company":"Spexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Balixafortide","moa":"CXCR4","graph1":"Nephrology","graph2":"Phase I","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spexis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spexis \/ Not Applicable"},{"orgOrder":0,"company":"Spexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Balixafortide","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spexis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Spexis \/ Not Applicable"},{"orgOrder":0,"company":"Spexis","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Colistimethate Sodium","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Spexis \/ SPRIM Global Investments","highestDevelopmentStatusID":"10","companyTruncated":"Spexis \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Spexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Murepavadin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Spexis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spexis \/ Not Applicable"},{"orgOrder":0,"company":"Spexis","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"Colistimethate Sodium","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Spexis \/ SPRIM Global Investments","highestDevelopmentStatusID":"10","companyTruncated":"Spexis \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Spexis","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Colistimethate Sodium","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Spexis \/ SPRIM Global Investments","highestDevelopmentStatusID":"10","companyTruncated":"Spexis \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Spexis","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Spexis \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"4","companyTruncated":"Spexis \/ Basilea Pharmaceutica"}]

    Find Clinical Drug Pipeline Developments & Deals by Spexis

    Menu

    Spexis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Basilea Pharmaceutica

                            Deal Size : $2.3 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Basilea Announces Acquisition of Preclinical Antibiotics Program from Spexis

                            Details : Through the acquisition, Basilea gains a preclinical program of antibiotics from a novel class, targeting Gram-negative bacteria, including multidrug-resistant strains.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 15, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Basilea Pharmaceutica

                            Deal Size : $2.3 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colistimethate Sodium

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : SPRIM Global Investments

                            Deal Size : $2.5 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Spexis Announces USD $2.5 Million Capital Commitment to Support the Upcoming Phase 3 ColiFin® Studies

                            Details : The financing will be used to fund the upcoming Phase 3 studies of ColiFin (colistimethate sodium), an inhaled antibiotic therapeutic for the management of chronic infections in cystic fibrosis patients.

                            Brand Name : ColiFin

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 15, 2023

                            Lead Product(s) : Colistimethate Sodium

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : SPRIM Global Investments

                            Deal Size : $2.5 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colistimethate Sodium

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : SPRIM Global Investments

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Spexis Announces Closing of Capital Commitment of USD 4.5 Million From SPRIM Global Investments (sgi) to Enabl...

                            Details : The net proceeds from the capital commitment will enable the initiation of the Phase 3 COPILOT study, the first part of the registrational clinical studies planned for ColiFin, an inhaled therapeutic for the management of chronic infections in cystic fib...

                            Brand Name : ColiFin

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            April 18, 2023

                            Lead Product(s) : Colistimethate Sodium

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : SPRIM Global Investments

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colistimethate Sodium

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : SPRIM Global Investments

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of ...

                            Details : This collaboration is expected to provide capitalization through significant clinical milestones in ColiFin®’s Phase 3 development. ColiFin® (colistimethate sodium) is being developed for the treatment of chronic lung infections in cystic fibrosis (C...

                            Brand Name : ColiFin

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 08, 2023

                            Lead Product(s) : Colistimethate Sodium

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : SPRIM Global Investments

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Murepavadin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spexis Reports Solid Safety and Pharmacokinetics Results from First-In-Human Study with Inhaled Murepavadin, a...

                            Details : Inhaled Murepavadin is an antibiotic targeting pseudomonas aeruginosa in cystic fibrosis, non-CF bronchiectasis. It binds to LptD and inhibits lipopolysaccharide transport function of LptD and causes lipopolysaccharide alterations in the bacterium and ul...

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            January 09, 2023

                            Lead Product(s) : Murepavadin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Balixafortide,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spexis Announces Promising Pre-clinical Data With Balixafortide In Combination With Various Therapies On The M...

                            Details : Balixafortide (POL6326), is a potent, specific and highly selective macrocycle inhibitor of CXCR4 that plays a role in a number of tumor types as well as non-oncology indications.

                            Brand Name : POL6326

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            December 13, 2022

                            Lead Product(s) : Balixafortide,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Balixafortide

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spexis Announces Positive Renal Impairment Clinical Trial Results With Balixafortide

                            Details : In this trial, POL6326 (balixafortide) was shown to be safe and well tolerated in all subjects, with only transient and mild-to-moderate manageable hypersensitivity-like events known to occur during initial drug infusion with CXCR4 inhibitors.

                            Brand Name : POL6326

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            September 22, 2022

                            Lead Product(s) : Balixafortide

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Balixafortide,Docetaxel

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : University of Michigan

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spexis' CXCR4 Inhibitor Balixafortide Demonstrates Synergistic Efficacy in Combination With Docetaxel in a Met...

                            Details : The preclinical study of metastatic prostate cancer combining POL6326 (balixafortide) and docetaxel (5 mg/kg once weekly) assessed tumor burden and tumor-induced bone degradation. Overall, results showed superior synergistic efficacy compared to either d...

                            Brand Name : POL6326

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            July 07, 2022

                            Lead Product(s) : Balixafortide,Docetaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : University of Michigan

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            Spexis

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : POL7306

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : CARB-X

                            Deal Size : $1.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Spexis Achieves First CARB-X Milestone for Its Thanatin Derivatives Program and Receives Funding of up to USD ...

                            Details : The award will support the continuation of the "thanatin derivatives program" including POL7306, belonging to Spexis' novel Outer Membrane Protein Targeting Antibiotic class of antibiotics to potentially treat life-threatening infections.

                            Brand Name : POL7306

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            March 03, 2022

                            Lead Product(s) : POL7306

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : CARB-X

                            Deal Size : $1.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth